2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to "A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands" by Dr. Germo Gericke.
Herrmann, Ken; Kratochwil, Clemens; Fendler, Wolfgang Pet al.
2021 • In European Journal of Nuclear Medicine and Molecular Imaging, 48 (9), p. 2668 - 2669
Dipeptides; Heterocyclic Compounds, 1-Ring; Ligands; PSMA-617; Radioisotopes; Prostate-Specific Antigen; Humans; Radiology, Nuclear Medicine and Imaging
Disciplines :
Radiology, nuclear medicine & imaging
Author, co-author :
Herrmann, Ken; Department of Nuclear Medicine, Universitätsklinikum Essen, Essen, Germany. Ken.Herrmann@uk-essen.de
Kratochwil, Clemens; German Cancer Research Center and Department of Nuclear Medicine, Universitätsklinikum Heidelberg, Heidelberg, Germany
Fendler, Wolfgang P; Department of Nuclear Medicine, Universitätsklinikum Essen, Essen, Germany
Eiber, Matthias; Klinikum rechts der Isar, Technische Universität München, Munich, Germany
Hustinx, Roland ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de médecine nucléaire et imagerie onco
Language :
English
Title :
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to "A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands" by Dr. Germo Gericke.
Publication date :
August 2021
Journal title :
European Journal of Nuclear Medicine and Molecular Imaging
ISSN :
1619-7070
eISSN :
1619-7089
Publisher :
Springer Science and Business Media Deutschland GmbH, Germany
The authors are active Nuclear Medicine practitioners and true believers in theranostics. Ken Herrmann reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics and personal fees from Pharma15, outside the submitted work. Clemens Kratochwil is a co-inventor of the PSMA-617 patent. Wolfgang P. Fendler was a consultant for BTG, and he received fees from RadioMedix, Bayer and Parexel outside of the submitted work. Matthias Eiber reports prior consulting activities for Blue Earth Diagnostics, Progenics Pharmaceuticals and Point Biopharma and a patent application for rhPSMA outside of the submitted work. No further conflicts of interest in regard to this letter to the editor.
Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, et al. EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands ((177)Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46:2536–44. 10.1007/s00259-019-04485-3. DOI: 10.1007/s00259-019-04485-3
Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer. 2021.
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797–804. 10.1016/S0140-6736(21)00237-3. DOI: 10.1016/S0140-6736(21)00237-3
Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Solnes LB, et al. A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer. Eur Urol. 2021. 10.1016/j.eururo.2021.03.004.
